CD38 and Miyoshi myopathy: Huang et al. have also reported the development of monoclonal anti-CD38 antibody–conjugated NPs in MM therapy [41] using NPs loaded with the S3I-1757 inhibitor of the STAT3, which is an oncoprotein that has proved to induce drug resistance in MM.